NasdaqGS - Nasdaq Real Time Price USD

Nautilus Biotechnology, Inc. (NAUT)

Compare
1.7100
-0.0600
(-3.39%)
At close: January 31 at 4:00:00 PM EST
1.7100
0.00
(0.00%)
After hours: January 31 at 4:02:45 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Sujal M. Patel Co-Founder, CEO, President, Secretary & Director 827.24k -- 1975
Dr. Parag Mallick Ph.D. Co-Founder, Chief Scientist & Director 562.8k -- 1977
Ms. Anna Mowry CFO & Treasurer 519.21k -- 1984
Mr. Matthew B. Murphy ESQ. General Counsel 382.64k -- 1965
Mr. Chris Blessington Vice President of Corporate Marketing & Communications -- -- --
Mr. Kentaro Suzuki Chief Marketing Officer -- -- --
Ms. Gwen E. Weld Chief People Officer 390.97k -- 1958
Mr. Nick A. Nelson Chief Business Officer & Senior VP of Business Development -- -- 1984
Dr. Subra Sankar Ph.D. Senior Vice President of Product Development 38.47k -- 1959

Nautilus Biotechnology, Inc.

2701 Eastlake Avenue East
Seattle, WA 98102
United States
206 333 2001 https://www.nautilus.bio
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
161

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Corporate Governance

Nautilus Biotechnology, Inc.’s ISS Governance QualityScore as of January 1, 2025 is 6. The pillar scores are Audit: 3; Board: 5; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

January 31, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 13, 2024 at 2:30 PM UTC

at Guggenheim Global Healthcare Conference

October 29, 2024 at 12:30 PM UTC

Q3 2024 Earnings Call

October 29, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

July 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 13, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 26, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

March 4, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

February 28, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers